Skip to main content
Professor Anthony Dorling
Professor Anthony Dorling

Professor Anthony Dorling

Professor of Transplant Inflammation and Repair

  • Co-Director of Nephrology, Urology & Transplantation

Research interests

  • Immunology

Biography

Anthony qualified in Medicine from the University of London in 1987 and gained membership of the Royal College of Physicians in 1990 (followed by Fellowship in 2005). He gained his PhD in Immunology from the Royal Postgraduate Medical School in 1996 and finished specialist training in nephrology before being appointed Senior Lecturer (later Reader) in Immunology at Imperial College (Hammersmith Hospital) in 2000. He moved to KCL, with Honorary Consultant status at Guy’s, in 2009. The theme of his research programme is ‘vascular inflammation’, focusing on the cellular and molecular mechanisms involved in vascular rejection. He has shown that coagulation proteases, such as thrombin, play a critical role in inflammatory vascular disease, including rejection and atherosclerosis. These same pathways are also involved in chronic arteriosclerosis and tissue fibrosis. He is co-inventor of a novel therapeutic, called Thrombalexin, that is expected to undergo first in man testing in 2019/20.  Clinically, he focuses on patients undergoing antibody-incompatible transplantation and in those with chronic rejection. His translational work has confirmed that B cells play a significant role in processing and presenting donor antigens in these patients, but has revealed a heterogeneous complexity that includes maintenance of tolerance mechanisms in a significant proportion of patients. He is co-PI of the large UK RCT OuTSMART.

    Research

    doring-group-banner-2
    Dorling Research Group

    The Dorling Group studies transplant inflammation and repair.

    News

    Optimising immunosuppression based on antibody testing does little to reduce kidney transplant failure rate

    Treating patients who possess transplant rejecting antibodies, using best available combinations of oral drugs, does not have an impact on transplant failure...

    Dialysis

    Researchers successfully model antibody-mediated transplant rejection in human kidneys

    The discovery may allow scientists to investigate new mechanisms and test treatment strategies for transplant rejection outside of the human body.

    Kidneys

    Events

    23DecERA-61-Congress-Stockholm-801x534

    MD test 16-10-23

    This symposium aims to test something with the pics

    Please note: this event has passed.

    07DecGuy's Hospital

    Guy's Hospital Kidney Transplantation Symposium 2023

    This symposium aims to provide an update on all aspects of Kidney transplantation carried out by expert clinicians in the field at Guy's Hospital - a leading...

    Please note: this event has passed.

      Research

      doring-group-banner-2
      Dorling Research Group

      The Dorling Group studies transplant inflammation and repair.

      News

      Optimising immunosuppression based on antibody testing does little to reduce kidney transplant failure rate

      Treating patients who possess transplant rejecting antibodies, using best available combinations of oral drugs, does not have an impact on transplant failure...

      Dialysis

      Researchers successfully model antibody-mediated transplant rejection in human kidneys

      The discovery may allow scientists to investigate new mechanisms and test treatment strategies for transplant rejection outside of the human body.

      Kidneys

      Events

      23DecERA-61-Congress-Stockholm-801x534

      MD test 16-10-23

      This symposium aims to test something with the pics

      Please note: this event has passed.

      07DecGuy's Hospital

      Guy's Hospital Kidney Transplantation Symposium 2023

      This symposium aims to provide an update on all aspects of Kidney transplantation carried out by expert clinicians in the field at Guy's Hospital - a leading...

      Please note: this event has passed.